|
|
Дата |
---|
04.08.2025 |
01.08.2025 |
31.07.2025 |
30.07.2025 |
29.07.2025 |
28.07.2025 |
25.07.2025 |
24.07.2025 |
23.07.2025 |
22.07.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.01
|
1.08
|
1.04
|
1.00
|
1.1099
|
1.005
|
|
|
79 062.52
|
305.00
|
1.02
|
1.12
|
1.06
|
1.02
|
1.114
|
1.04
|
|
|
75 510.45
|
222.00
|
1.02
|
1.14
|
1.04
|
1.035
|
1.14
|
1.08
|
|
|
136 663.12
|
380.00
|
1.04
|
1.08
|
1.08
|
1.045
|
1.08
|
1.05
|
|
|
54 559.97
|
182.00
|
1.02
|
1.05
|
1.07
|
1.02
|
1.08
|
1.05
|
|
|
112 032.63
|
396.00
|
1.01
|
1.12
|
1.05
|
0.99
|
1.12
|
1.07
|
|
|
150 509.81
|
633.00
|
1.02
|
1.10
|
1.11
|
1.0107
|
1.1379
|
1.06
|
|
|
59 308.46
|
223.00
|
1.11
|
1.15
|
1.08
|
1.05
|
1.17
|
1.105
|
|
|
208 884.93
|
472.00
|
1.03
|
1.07
|
0.93
|
0.8954
|
1.11
|
1.08
|
|
|
265 852.41
|
587.00
|
0.8605
|
0.92
|
0.899
|
0.84
|
0.92
|
0.901
|
|
|
65 120.78
|
219.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть